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Introduction
Prognosis varies dramatically in head and neck squamous
cell carcinoma (HNSCC) based on HPV status. In HPV+
patients, programmed death (PD)-1 expression has been
linked to a better clinical outcome. We hypothesized that
extent of PD-1 expression may differentially impact T cell
phenotype, patient prognosis and response to anti-PD-1
immunotherapy in a murine HPV+ cancer model.
Material and methods
Freshly isolated tumor infiltrating lymphocytes (TIL) from
HNSCC patients were stained by flow cytometry for
expression level of PD-1 expression (PD-1high vs. PD-1low),
granzyme B, or IFN-y secretion by ELISPOT. The prog-
nostic impact of PD-1high vs. PD-1low T cells was deter-
mined in a cohort of HNSCC patients (n=56, median
follow up=19 mo). In a murine HNSCC model, PD-1high
and PD-1low fractions were compared from CD3+ CD8+
PD-1+ cells and analyzed according to different treatment
groups (untreated, anti-PD-1 mAb, radiotherapy and
3 different anti-PD-1/radiotherapy combinations).
Results
CTLA-4 and PD-1 were significantly upregulated on both
HPV+ and HPV- HNSCC patients’ TIL, whereas PD-1+
CD8+ cells were significantly enriched in TIL from HPV+
patients (p=0.006). Interestingly, PD-1high cells represen-
ted a more dysfunctional phenotype, with severely
compromised IFN-g secretion (phigh CD8+ TIL were
more likely to be HPV- and had a worse disease free survi-
val (HR = 2.25; 95% CI = 1.46 – 3.15; p < .0001), while
high fractions of PD-1low T cells were associated with bet-
ter clinical outcome (HR= 0.19, 95% CI = .07 - .49,
p = .0006), and were seen preferentially in HPV+ HNSCC
patients. In the murine HNSCC model, anti-PD-1 mAb
plus radiotherapy resulted in optimal tumor elimination,
which was associated with an elimination of PD-1high
CD8+ T cells and – most importantly – increase in
PD-1low/intermed T cell frequencies (p < 0.5).
Discussion
Consideration of different PD-1 expression levels on TIL
segregates PD-1 expression as a marker of activated,
competent tumor reactive T cells on the one hand (low/
intermed expression), and as a marker of exhausted,
dysfunctional cells in the tumor microenvironment on the
other hand (high expression). These results emphasize the
crucial role of differential PD-1 expression levels on
HNSCC patients’ effector T cells for prognosis and as a
potential novel biomarker for anti-PD-1/PD-L1 based
immunotherapy.
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